Back to resultsMulticentric Randomised Trial for Resectable Gastric Cancer (CRITICS-II)
Primary Purpose
Gastric Cancer
Status
Recruiting
Phase
Phase 2
Locations
Netherlands
Study Type
Interventional
Intervention
Docetaxel
Oxaliplatin
Capecitabine
gastrectomy
radiotherapy of gastric cancer
Paclitaxel
Carboplatin
Sponsored by
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring gastric cancer, radiotherapy, chemoradiotherapy
Eligibility Criteria
Inclusion Criteria:
- TNM 8th ed stage IB-IIIC gastric cancer (histologically proven); tumour bulk has to be in the stomach but may involve gastro-oesophageal junction
- WHO < 2
- Age ≥ 18 yrs
- Resectable adenocarcinoma of the stomach or gastro-oesophageal junction
- No prior abdominal radiotherapy
- Haematology: Hb ≥5.0 mmol/l; leukocytes≥3.0x109/l, neutrophils ≥1.5x109/l, thrombocytes ≥100x109/l
- Renal function: serum creatinine ≤1.25x ULN, creatinine clearance ≥ 50 ml/min (calculated by Cockcroft and Gault formula) Liver function: total bilirubin ≤1.5x ULN, alkaline phosphatase and ASAT/ALAT ≤ 3x ULN
- At staging laparoscopy (mandatory) obtained biopsies of suspected peritoneal lesions and/or substantial free peritoneal fluid if any should be pathologically proven tumor negative
- Written informed consent
- Expected adequacy of follow-up
- Caloric intake≥1500 kcal/day, verified by a dietician before registration.
- if caloric intake is < 1500 kcal/day or if bodyweight has decreased > 10% over the last 6 months or > 5% over the last month, dietary intervention such as oral nutritional support or enteral tube feeding is mandatory
Exclusion Criteria:
- T1N0 disease (assessed by endoscopic ultrasound)
- Distant metastases
- Inoperable patients; due to technical surgery-related factors or general condition
- Previous malignancy, except adequately treated non-melanoma skin cancer or in-situ cancer of the cervix uteri; in case of a previous other malignancy with a disease-free period≥5 years, inclusion can be accepted after consultation of the principal investigator
- Solitary functioning kidney that will be within the radiation field
- Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery
- Uncontrolled (bacterial) infections
- Significant concomitant diseases preventing the safe administration of study drugs or likely to interfere with study assessments
- Uncontrolled angina pectoris, cardiac failure or clinically significant arrhythmias
- Continuous use of immunosuppressive agents equivalent to >10 mg daily prednison
- Concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine
- Neurotoxicity > CTC grade 1
- Pregnancy or breast feeding
- Patients (M/F) with reproductive potential not implementing adequate contraceptive measures
- Gastric or gastro-esophageal stent within radiation field
Sites / Locations
- Medisch Centrum LeeuwardenRecruiting
- Radiotherapeutisch Instituut Friesland
- Gelre Ziekenhuizen
- Gelre Ziekenhuizen
- Zuyderland Medisch CentrumRecruiting
- Viecuri Medisch CentrumRecruiting
- Elkerliek
- Catharina ZiekenhuisRecruiting
- Maxima Medisch Centrum
- St. Anna Zorggroep
- Elkerliek
- Instituut Verbeeten
- Bernhoven
- Maxima Medisch Centrum
- Spaarne Gasthuis
- Ziekenhuisgroep TwenteRecruiting
- Deventer ZiekenhuisRecruiting
- Medisch Spectrum TwenteRecruiting
- Leids Universitair Medisch CentrumRecruiting
- Reinier de Graaf GasthuisRecruiting
- Jeroen Bosch Ziekenhuis
- Netherlands Cancer InstituutRecruiting
- Academisch Medisch CentrumRecruiting
- RijnstateRecruiting
- HAGA ziekenhuis
- Ziekenhuis Gelderse Vallei
- Universitair Medisch Centrum Groningen
- Ziekenhuis St AntoniusRecruiting
- Elisabeth Tweesteden ZiekenhuisRecruiting
- Universitair Medisch Centrum UtrechtRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
neo-adjuvant chemotherapy followed by surgery
neo-adjuvant chemo and subsequent CRT followed by surgery
neo-adjuvant chemoradiotherapy followed by surgery
Arm Description
4 courses of 3 weekly DOC followed by surgery
2 courses of 3 weekly DOC and subsequent CRT followed by surgery
chemoradiotherapy followed by surgery
Outcomes
Primary Outcome Measures
Event-Free survival
Event-free survival will be measured by clinical outcome and CT-scan
Secondary Outcome Measures
Time to Event (events: local recurrence, regional recurrence, local-regional recurrence or progression, distant recurrence, or death from any cause)
Interval between randomization and event measured by clinical outcome and CT scan
Time to recurrence (events: local recurrence, regional recurrence, local-regional recurrence or progression, distant recurrence)
Interval between randomization and recurrence determined by clinical outcome and CT scan
Toxicity
Number of patients with treatment-related adverse events as assessed by CTCAE v4.0
Full Information
NCT ID
NCT02931890
First Posted
September 14, 2016
Last Updated
October 26, 2022
Sponsor
The Netherlands Cancer Institute
1. Study Identification
Unique Protocol Identification Number
NCT02931890
Brief Title
Multicentric Randomised Trial for Resectable Gastric Cancer
Acronym
CRITICS-II
Official Title
A Multicentre Randomised Phase II Trial of Neo-adjuvant Chemotherapy Followed by Surgery vs. Neo-adjuvant Chemotherapy and Subsequent Chemoradiotherapy Followed by Surgery vs. Neo-adjuvant Chemoradiotherapy Followed by Surgery in Resectable Gastric Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 21, 2017 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2029 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Netherlands Cancer Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The CRITICS-II trial aims to identify the optimal preoperative regimen in resectable gastric cancer by comparing three investigational treatment arms: chemotherapy vs. chemotherapy and subsequent chemoradiotherapy vs. chemoradiotherapy. The rationale behind this trial design is based on the following concepts:
Preoperative treatment is associated with better patient compliance than postoperative regimens
Preoperative treatment increases the likelihood of disease downsizing/downstaging and radical R0 resections
Preoperative paclitaxel/carboplatin-based concurrent chemoradiotherapy and DOC chemotherapy are effective, feasible and safe regimens
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer
Keywords
gastric cancer, radiotherapy, chemoradiotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
207 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
neo-adjuvant chemotherapy followed by surgery
Arm Type
Active Comparator
Arm Description
4 courses of 3 weekly DOC followed by surgery
Arm Title
neo-adjuvant chemo and subsequent CRT followed by surgery
Arm Type
Active Comparator
Arm Description
2 courses of 3 weekly DOC and subsequent CRT followed by surgery
Arm Title
neo-adjuvant chemoradiotherapy followed by surgery
Arm Type
Active Comparator
Arm Description
chemoradiotherapy followed by surgery
Intervention Type
Drug
Intervention Name(s)
Docetaxel
Other Intervention Name(s)
Taxotere
Intervention Description
3 weekly course of docetaxel i.v in arm 1 and 2
Intervention Type
Drug
Intervention Name(s)
Oxaliplatin
Other Intervention Name(s)
Eloxatin
Intervention Description
3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2
Intervention Type
Drug
Intervention Name(s)
Capecitabine
Other Intervention Name(s)
Xeloda
Intervention Description
oral capecitabine in arm 1 and 2
Intervention Type
Procedure
Intervention Name(s)
gastrectomy
Intervention Description
resection of gastric cancer after pre-operative chemotherapy for all arms
Intervention Type
Radiation
Intervention Name(s)
radiotherapy of gastric cancer
Intervention Description
5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
5 weeks of paclitaxel i.v once a week (in arm 2 and 3)
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
5 weeks of carboplatin i.v once a week (in arm 2 and 3)
Primary Outcome Measure Information:
Title
Event-Free survival
Description
Event-free survival will be measured by clinical outcome and CT-scan
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Time to Event (events: local recurrence, regional recurrence, local-regional recurrence or progression, distant recurrence, or death from any cause)
Description
Interval between randomization and event measured by clinical outcome and CT scan
Time Frame
1 year
Title
Time to recurrence (events: local recurrence, regional recurrence, local-regional recurrence or progression, distant recurrence)
Description
Interval between randomization and recurrence determined by clinical outcome and CT scan
Time Frame
1 year
Title
Toxicity
Description
Number of patients with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
TNM 8th ed stage IB-IIIC gastric cancer (histologically proven); tumour bulk has to be in the stomach but may involve gastro-oesophageal junction
WHO < 2
Age ≥ 18 yrs
Resectable adenocarcinoma of the stomach or gastro-oesophageal junction
No prior abdominal radiotherapy
Haematology: Hb ≥5.0 mmol/l; leukocytes≥3.0x109/l, neutrophils ≥1.5x109/l, thrombocytes ≥100x109/l
Renal function: serum creatinine ≤1.25x ULN, creatinine clearance ≥ 50 ml/min (calculated by Cockcroft and Gault formula) Liver function: total bilirubin ≤1.5x ULN, alkaline phosphatase and ASAT/ALAT ≤ 3x ULN
At staging laparoscopy (mandatory) obtained biopsies of suspected peritoneal lesions and/or substantial free peritoneal fluid if any should be pathologically proven tumor negative
Written informed consent
Expected adequacy of follow-up
Caloric intake≥1500 kcal/day, verified by a dietician before registration.
if caloric intake is < 1500 kcal/day or if bodyweight has decreased > 10% over the last 6 months or > 5% over the last month, dietary intervention such as oral nutritional support or enteral tube feeding is mandatory
Exclusion Criteria:
T1N0 disease (assessed by endoscopic ultrasound)
Distant metastases
Inoperable patients; due to technical surgery-related factors or general condition
Previous malignancy, except adequately treated non-melanoma skin cancer or in-situ cancer of the cervix uteri; in case of a previous other malignancy with a disease-free period≥5 years, inclusion can be accepted after consultation of the principal investigator
Solitary functioning kidney that will be within the radiation field
Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery
Uncontrolled (bacterial) infections
Significant concomitant diseases preventing the safe administration of study drugs or likely to interfere with study assessments
Uncontrolled angina pectoris, cardiac failure or clinically significant arrhythmias
Continuous use of immunosuppressive agents equivalent to >10 mg daily prednison
Concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine
Neurotoxicity > CTC grade 1
Pregnancy or breast feeding
Patients (M/F) with reproductive potential not implementing adequate contraceptive measures
Gastric or gastro-esophageal stent within radiation field
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marcel Verheij, MD, PhD
Phone
+31 20 512 9111
Email
m.verheij@nki.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Romy van Amelsfoort, MD
Phone
+31 20 512 9111
Email
epm.jansen@nki.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marcel Verheij, MD, PhD
Organizational Affiliation
The Netherlands Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medisch Centrum Leeuwarden
City
Leeuwarden
State/Province
Friesland
ZIP/Postal Code
8901BR
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marco B Polee, MD,PhD
Phone
+31 58 286 6963
Facility Name
Radiotherapeutisch Instituut Friesland
City
Leeuwarden
State/Province
Friesland
ZIP/Postal Code
8934AD
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vera Oppedijk, MD
Email
v.oppedijk@skf-rif.nl
Facility Name
Gelre Ziekenhuizen
City
Apeldoorn
State/Province
Gelderland
ZIP/Postal Code
7334DZ
Country
Netherlands
Individual Site Status
Withdrawn
Facility Name
Gelre Ziekenhuizen
City
Zutphen
State/Province
Gelderland
ZIP/Postal Code
7207AE
Country
Netherlands
Individual Site Status
Withdrawn
Facility Name
Zuyderland Medisch Centrum
City
Sittard-Geleen
State/Province
Limburg
ZIP/Postal Code
6162 BG
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frank PJ Peters, MD
Phone
+31 88 459 7777
Email
f.peters@zuyderland.nl
Facility Name
Viecuri Medisch Centrum
City
Venlo
State/Province
Limburg
ZIP/Postal Code
5912 BL
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yes J van de Wouw, MD, PhD
Phone
+31 077 320 5555
Email
yvdwouw@viecuri.nl
Facility Name
Elkerliek
City
Deurne
State/Province
Noord Brabant
ZIP/Postal Code
5751 CB
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeroen Vincent, MD
Phone
+31 493 32 88 88
Email
j.vincent@elkerliek.nl
Facility Name
Catharina Ziekenhuis
City
Eindhoven
State/Province
Noord Brabant
ZIP/Postal Code
5602 ZA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grard AP Nieuwenhuijzen, MD, PhD
Phone
+31 40 239 66 00
Email
grard.nieuwenhuijzen@catharinaziekenhuis.nl
Facility Name
Maxima Medisch Centrum
City
Eindhoven
State/Province
Noord Brabant
ZIP/Postal Code
5631 BM
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lieke HJ Simkens, MD, PhD
Phone
+31 40 8885320
Email
l.simkens@mmc.nl
Facility Name
St. Anna Zorggroep
City
Geldrop
State/Province
Noord Brabant
ZIP/Postal Code
5664 EH
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arno EM Smals, MD, PhD
Phone
+31 40 286 4040
Email
a.smals@st-anna.nl
Facility Name
Elkerliek
City
Helmond
State/Province
Noord Brabant
ZIP/Postal Code
5707 HA
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeroen Vincent, MD
Phone
+31 492 59 55 55
Email
j.vincent@elkerliek.nl
Facility Name
Instituut Verbeeten
City
Tilburg
State/Province
Noord Brabant
ZIP/Postal Code
5022 GC
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tom Rozema, MD
Phone
+31 13 594 77 77
Email
rozema.t@bvi.nl
Facility Name
Bernhoven
City
Uden
State/Province
Noord Brabant
ZIP/Postal Code
5406 PT
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Allert H Vos, MD
Phone
+31 413 - 40 19 41
Email
a.vos@bernhoven.nl
Facility Name
Maxima Medisch Centrum
City
Veldhoven
State/Province
Noord Brabant
ZIP/Postal Code
5504 DB
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lieke HJ Simkens, MD, PhD
Phone
+31 40 8885320
Email
l.simkens@mmc.nl
Facility Name
Spaarne Gasthuis
City
Hoofddorp
State/Province
Noord-Holland
ZIP/Postal Code
2000 AK
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aart Beeker, MD
Phone
+31 023 224 5805
Email
abeeker@spaarnegasthuis.nl
Facility Name
Ziekenhuisgroep Twente
City
Almelo
State/Province
Overijssel
ZIP/Postal Code
7609 PP
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ronald Hoekstra, MD, PhD
Phone
+31 88 708 4087
Email
r.hoekstra@zgt.nl
Facility Name
Deventer Ziekenhuis
City
Deventer
State/Province
Overijssel
ZIP/Postal Code
7416 SE
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lonneke L.W. Kessels, MD
Phone
+31 57 053 6437
Email
researchoncologie@dz.nl
Facility Name
Medisch Spectrum Twente
City
Enschede
State/Province
Overijssel
ZIP/Postal Code
7512 KZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leonie J.M Mekenkamp, MD, PhD
Phone
+31 53 487 2000
Email
l.mekenkamp@mst.nl
Facility Name
Leids Universitair Medisch Centrum
City
Leiden
State/Province
Zuid Holland
ZIP/Postal Code
2333 ZA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henk H Hartgrink, MD, PhD
Phone
+31 71 526 4005
Email
h.h.hartgrink@lumc.nl
Facility Name
Reinier de Graaf Gasthuis
City
Delft
State/Province
Zuid-Holland
ZIP/Postal Code
2625 AD
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annelie J.E. Vulink, MD, PhD
Phone
+31 15 260 3107
Email
a.vulink@rdgg.nl
Facility Name
Jeroen Bosch Ziekenhuis
City
's-Hertogenbosch
ZIP/Postal Code
5223 GZ
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jolien Tol, MD, PhD
Phone
+21 73 553 2000
Email
j.tol@jbz.nl
Facility Name
Netherlands Cancer Instituut
City
Amsterdam
ZIP/Postal Code
1066CX
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marcel Verheij, MD, PhD
Phone
+31 243614023
Email
marcel.verheij@radboudumc.nl
First Name & Middle Initial & Last Name & Degree
Romy van Amelsfoort, MD
Phone
+31 20 512 9111
Email
criticstrials@nki.nl
Facility Name
Academisch Medisch Centrum
City
Amsterdam
ZIP/Postal Code
1105AZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hanneke van Laarhoven, MD, PhD
Phone
+31 20 566 5955
Email
h.vanlaarhoven@amsterdamumc.nl
First Name & Middle Initial & Last Name & Degree
Maarten C Hulshof, MD, PhD
Phone
+31 20 566 5955
Email
m.c.hulshof@amsterdamumc.nl
Facility Name
Rijnstate
City
Arnhem
ZIP/Postal Code
6815AD
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Theo v Voorthuizen, MD,PhD
Phone
+31 26 3786735
Email
tvanvoorthuizen@rijnstate.nl
Facility Name
HAGA ziekenhuis
City
Den Haag
ZIP/Postal Code
2545AA
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patricia Quarles van Ufford-Mannesse, MD
Phone
+31 70 210 0000
Facility Name
Ziekenhuis Gelderse Vallei
City
Ede
ZIP/Postal Code
6716RP
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maartje Verstappen, MD, PhD
Phone
+31 318 434608
Email
verstappenm@zgv.nl
Facility Name
Universitair Medisch Centrum Groningen
City
Groningen
ZIP/Postal Code
9713 GZ
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Boudewijn van Etten, MD, PhD
Phone
+31 50 361 2317
Email
b.van.etten@umcg.nl
Facility Name
Ziekenhuis St Antonius
City
Nieuwegein
ZIP/Postal Code
3435CM
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maartje Los, MD, PhD
Phone
+31 88 320 3000
Email
m.los@antoniusziekenhuis.nl
Facility Name
Elisabeth Tweesteden Ziekenhuis
City
Tilburg
ZIP/Postal Code
5022GC
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurens Beerepoot, MD, PhD
Phone
+31 13 221 00 00
Email
l.beerepoot@elisabeth.nl
Facility Name
Universitair Medisch Centrum Utrecht
City
Utrecht
ZIP/Postal Code
3508 GA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Richard van Hillergersberg, MD, PhD
Phone
+31 88 75 580 74
Email
r.vanhillergersberg@umcutrecht.nl
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30200910
Citation
Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018 Sep 10;18(1):877. doi: 10.1186/s12885-018-4770-2.
Results Reference
derived
Learn more about this trial
Multicentric Randomised Trial for Resectable Gastric Cancer
We'll reach out to this number within 24 hrs